Neximmune Stock Beta
NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company Beta Analysis
Neximmune's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Neximmune Beta | 1.94 |
Most of Neximmune's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Neximmune has a Beta of 1.937. This is 125.23% higher than that of the Biotechnology sector and 39.35% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Neximmune Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neximmune will likely underperform.
Neximmune Fundamentals
Return On Equity | -1.96 | ||||
Return On Asset | -0.7 | ||||
Current Valuation | (491.95 K) | ||||
Shares Outstanding | 1.37 M | ||||
Shares Owned By Insiders | 17.00 % | ||||
Shares Owned By Institutions | 11.17 % | ||||
Number Of Shares Shorted | 15.99 K | ||||
Price To Book | 1.38 X | ||||
EBITDA | (28.17 M) | ||||
Net Income | (32.34 M) | ||||
Cash And Equivalents | 53.13 M | ||||
Cash Per Share | 2.20 X | ||||
Total Debt | 68.81 K | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 6.54 X | ||||
Book Value Per Share | 2.00 X | ||||
Cash Flow From Operations | (31.43 M) | ||||
Short Ratio | 2.26 X | ||||
Earnings Per Share | (24.11) X | ||||
Target Price | 2.0 | ||||
Beta | 1.94 | ||||
Market Capitalization | 3.25 M | ||||
Total Asset | 8.59 M | ||||
Retained Earnings | (222.59 M) | ||||
Working Capital | 316.73 K | ||||
Net Asset | 8.59 M |
About Neximmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neximmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neximmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neximmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |